Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells 15,000 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin Mcculloch sold 15,000 shares of the company’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $8.00, for a total transaction of $120,000.00. Following the completion of the transaction, the insider owned 1,685,426 shares in the company, valued at $13,483,408. This trade represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Xeris Biopharma Trading Down 2.5%

NASDAQ XERS traded down $0.20 during trading on Friday, reaching $7.93. The company’s stock had a trading volume of 2,752,148 shares, compared to its average volume of 3,548,245. The firm has a 50 day moving average price of $7.40 and a 200 day moving average price of $7.14. Xeris Biopharma Holdings, Inc. has a 12 month low of $3.14 and a 12 month high of $10.08. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of -79.29 and a beta of 0.50.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, November 6th. The company reported $0.00 EPS for the quarter, missing the consensus estimate of $0.01 by ($0.01). The firm had revenue of $74.38 million for the quarter, compared to the consensus estimate of $74.19 million. On average, equities analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Xeris Biopharma

A number of institutional investors have recently added to or reduced their stakes in XERS. Calamos Advisors LLC bought a new position in shares of Xeris Biopharma in the 3rd quarter valued at $1,116,000. AQR Capital Management LLC grew its position in Xeris Biopharma by 13.4% during the 1st quarter. AQR Capital Management LLC now owns 946,766 shares of the company’s stock worth $5,198,000 after acquiring an additional 111,826 shares during the last quarter. Voya Investment Management LLC increased its holdings in Xeris Biopharma by 866.6% in the 3rd quarter. Voya Investment Management LLC now owns 400,079 shares of the company’s stock worth $3,257,000 after purchasing an additional 358,689 shares in the last quarter. Squarepoint Ops LLC increased its holdings in Xeris Biopharma by 1,679.1% in the 2nd quarter. Squarepoint Ops LLC now owns 284,567 shares of the company’s stock worth $1,329,000 after purchasing an additional 268,572 shares in the last quarter. Finally, Savvy Advisors Inc. bought a new position in Xeris Biopharma in the second quarter valued at about $189,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on XERS. Piper Sandler increased their target price on Xeris Biopharma from $6.00 to $8.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a research note on Friday. Oppenheimer reissued an “outperform” rating and issued a $18.00 target price on shares of Xeris Biopharma in a report on Friday, November 7th. Zacks Research downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 30th. Finally, Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 8th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $9.50.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.